international project to develop the bank accessed worldwide new models of cancer cells for research -
An international project to develop a large bank, accessible to global new culture models of cancer cells from the research community launched today. The National Cancer Institute (NCI), part of the National Institutes of Health; Cancer Research UK, London, England; the Wellcome Trust Sanger Institute, Cambridge, England; and Hubrecht organoid Technology Foundation, Utrecht, Netherlands, joined forces to develop the initiative on models of human cancer (HCMI) will bring together expertise from around the world to about 1,000 models of cancer cells.
Using new techniques to grow cells, scientists can make models that will better resemble the tissue architecture and the complexity of human tumors than the cell lines used today.
Louis Staudt, MD, Ph.D., director of NCI's Center for Cancer Genomics, said, "in the context of the Initiative for NCI precision medicine in oncology, this new project is perfectly timed to take advantage of the latest cell cultures and genomic sequencing techniques to create models that are representative of patients with tumors and annotated genomic and clinical information. This effort is a first step toward learning how to use these tools to design individualized treatments. "
genetic sequence data derived tumors and models will be available to researchers, and clinical data on patients and their tumors. All model information will be shared in a way that protects patient privacy.
Ian Walker, Ph.D., director of Cancer Research UK Clinical Research and Strategic Partnerships, said: "This exciting new means of projects that we can expand our resources to researchers around the world . We want scientists have the best resources to be able to easily explore all types of cancer. and these new cell lines could transform the way we look at cancer and could help develop better treatments for patients. "
scientists make models using tissue from patients with different types of cancer, including potentially rare cancers and children, who are often under-represented or not at all available in the lines of collections existing cell. The new models have the potential to reflect tumor biology more accurately and better represent the overall population of patients with cancer.
The HCMI collaborators aim to accelerate the development of new models and make research more efficient by avoiding unnecessary duplication of scientific efforts.
Mathew Garnett, Ph.D., group leader at the Wellcome Trust Sanger Institute, said: "the new bypass technologies cancer models allow us to generate more and improved models for cancer research. A concerted and coordinated effort to make new models will accelerate this process, while allowing rapid learning, the sharing protocol, and standard culture methods. "
HCMI could transform research and enable scientists to study many aspects of cellular biology and cancer, including how the disease progresses, drug resistance, and the development of treatments . precision medicine
Hans Clevers, MD, Ph.D., of the Hubrecht foundation organoid Technology, said: "We are delighted to be part of this global partnership to new resources for researchers" .
Using new techniques to grow cells, scientists can make models that will better resemble the tissue architecture and the complexity of human tumors than the cell lines used today.
Louis Staudt, MD, Ph.D., director of NCI's Center for Cancer Genomics, said, "in the context of the Initiative for NCI precision medicine in oncology, this new project is perfectly timed to take advantage of the latest cell cultures and genomic sequencing techniques to create models that are representative of patients with tumors and annotated genomic and clinical information. This effort is a first step toward learning how to use these tools to design individualized treatments. "
genetic sequence data derived tumors and models will be available to researchers, and clinical data on patients and their tumors. All model information will be shared in a way that protects patient privacy.
Ian Walker, Ph.D., director of Cancer Research UK Clinical Research and Strategic Partnerships, said: "This exciting new means of projects that we can expand our resources to researchers around the world . We want scientists have the best resources to be able to easily explore all types of cancer. and these new cell lines could transform the way we look at cancer and could help develop better treatments for patients. "
scientists make models using tissue from patients with different types of cancer, including potentially rare cancers and children, who are often under-represented or not at all available in the lines of collections existing cell. The new models have the potential to reflect tumor biology more accurately and better represent the overall population of patients with cancer.
The HCMI collaborators aim to accelerate the development of new models and make research more efficient by avoiding unnecessary duplication of scientific efforts.
Mathew Garnett, Ph.D., group leader at the Wellcome Trust Sanger Institute, said: "the new bypass technologies cancer models allow us to generate more and improved models for cancer research. A concerted and coordinated effort to make new models will accelerate this process, while allowing rapid learning, the sharing protocol, and standard culture methods. "
HCMI could transform research and enable scientists to study many aspects of cellular biology and cancer, including how the disease progresses, drug resistance, and the development of treatments . precision medicine
Hans Clevers, MD, Ph.D., of the Hubrecht foundation organoid Technology, said: "We are delighted to be part of this global partnership to new resources for researchers" .
EmoticonEmoticon